These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24120570)

  • 1. Transient replication of a hepatitis C virus genotype 1b replicon chimera encoding NS5A-5B from genotype 3a.
    Kylefjord H; Danielsson A; Sedig S; Belda O; Wiktelius D; Vrang L; Targett-Adams P
    J Virol Methods; 2014 Jan; 195():156-63. PubMed ID: 24120570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of full-length cell-culture infectious clone and subgenomic replicon for a genotype 3a isolate of hepatitis C virus.
    Chen M; Xu Y; Li N; Yin P; Zhou Q; Feng S; Wu T; Wei L; Wang H; Fu Y; Li YP
    J Gen Virol; 2021 Dec; 102(12):. PubMed ID: 34949310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Replication efficiency of chimeric replicon containing NS5A-5B genes derived from HCV-infected patient sera.
    Tripathi RL; Krishnan P; He Y; Middleton T; Pilot-Matias T; Chen CM; Lau DT; Lemon SM; Mo H; Kati W; Molla A
    Antiviral Res; 2007 Jan; 73(1):40-9. PubMed ID: 16914212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust and persistent replication of the genotype 6a hepatitis C virus replicon in cell culture.
    Yu M; Peng B; Chan K; Gong R; Yang H; Delaney W; Cheng G
    Antimicrob Agents Chemother; 2014 May; 58(5):2638-46. PubMed ID: 24550344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of interaction between hepatitis C virus NS5A and NS5B on hepatitis C virus RNA replication with the hepatitis C virus replicon.
    Shimakami T; Hijikata M; Luo H; Ma YY; Kaneko S; Shimotohno K; Murakami S
    J Virol; 2004 Mar; 78(6):2738-48. PubMed ID: 14990694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
    McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
    Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
    Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
    Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon.
    Ward JC; Bowyer S; Chen S; Fernandes Campos GR; Ramirez S; Bukh J; Harris M
    J Gen Virol; 2020 Nov; 101(11):1182-1190. PubMed ID: 32897181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
    Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
    J Virol; 2019 May; 93(10):. PubMed ID: 30842319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
    Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
    Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
    Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
    Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Replicons of a Rodent Hepatitis C Model Virus Permit Selection of Highly Permissive Cells.
    Wolfisberg R; Holmbeck K; Nielsen L; Kapoor A; Rice CM; Bukh J; Scheel TKH
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice.
    Osawa M; Uchida T; Imamura M; Teraoka Y; Fujino H; Nakahara T; Ono A; Murakami E; Kawaoka T; Miki D; Tsuge M; Hiramatsu A; Abe-Chayama H; Hayes CN; Makokha GN; Aikata H; Ishida Y; Tateno C; Miyayama Y; Hijikata M; Chayama K
    J Gen Virol; 2019 Jul; 100(7):1123-1131. PubMed ID: 31199224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Establishment of robust HCV genotype 4d, 5a, and 6a replicon systems.
    Camus G; Xu S; Han B; Lu J; Dvory-Sobol H; Yu M; Cheng G; Miller MD; Doehle BP; Mo H
    Virology; 2018 Jan; 514():134-141. PubMed ID: 29175627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.
    Bartolini B; Giombini E; Taibi C; Lionetti R; Montalbano M; Visco-Comandini U; D'Offizi G; Capobianchi MR; McPhee F; Garbuglia AR
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28783119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C.
    Di Maio VC; Barbaliscia S; Teti E; Fiorentino G; Milana M; Paolucci S; Pollicino T; Morsica G; Starace M; Bruzzone B; Gennari W; Micheli V; Yu La Rosa K; Foroghi L; Calvaruso V; Lenci I; Polilli E; Babudieri S; Aghemo A; Raimondo G; Sarmati L; Coppola N; Pasquazzi C; Baldanti F; Parruti G; Perno CF; Angelico M; Craxì A; Andreoni M; Ceccherini-Silberstein F;
    Liver Int; 2021 Aug; 41(8):1802-1814. PubMed ID: 33497016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.
    Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K
    Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dominant negative effect of wild-type NS5A on NS5A-adapted subgenomic hepatitis C virus RNA replicon.
    Graziani R; Paonessa G
    J Gen Virol; 2004 Jul; 85(Pt 7):1867-1875. PubMed ID: 15218171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.
    Paolucci S; Fiorina L; Mariani B; Gulminetti R; Novati S; Barbarini G; Bruno R; Baldanti F
    Virol J; 2013 Dec; 10():355. PubMed ID: 24341898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.